moneyheap
XNCR · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Xencor, Inc. (XNCR) stock moving?
XNCR has rallied from a 25.18 close on Oct 23 to 39.39 on Nov 10, a gain of about 56%, and closed at the highest level of the 30-day window on Nov 10. The move started Oct 26, when the stock jumped from 25.18 to a 29.18 close on 8.9M shares, about six times the typical volume, after an 8-K presenting updated Phase 1 dose-expansion results for XmAb819 in advanced clear cell renal cell carcinoma. The Q3 2026 report on Nov 4 then drove the stock up 14.3% to 35.03 on 2.5M shares, with revenue of $116.5M and EPS of $0.50 far above estimates. Estimates differed between sources ($63.0M and $78.6M for revenue), and the size of the beat may reflect non-recurring items, which the filings reviewed here do not clarify. On Nov 9 the company reported initial Phase 1b plamotamab data in rheumatoid arthritis and started first-in-human testing of XmAb412. Partner Vir Biotechnology's Phase 3 results for a regimen using Xencor's Xtend technology met their endpoints, and the stock rose 7.9% to 38.59 on 1.96M shares. Cantor Fitzgerald reiterated Overweight with a $70 target on Nov 5, and Wells Fargo, RBC and Wedbush also updated their ratings on Nov 2. Volume has eased from the peak, and the stock is now well above the Oct 23 base, so much of the news appears priced in. Early-stage pipeline data and the lumpy nature of collaboration revenue leave longer-term outcomes uncertain.
News behind the analysis
- Xencor, Inc. Reports Q3 2026 Financial ResultsXencor reported Q3 2026 revenue of $116.5 million and EPS of $0.50, both well above analyst expectations.
- Xencor Q3 EPS $0.50 Beats $(0.73) Estimate, Sales $116.520M Beat $78.587M EstimateBenzinga reported the Q3 EPS and sales beat versus consensus, with sales of $116.52M against a $78.59M estimate.
- Cantor Fitzgerald Reiterates Overweight on Xencor, Maintains $70 Price TargetCantor Fitzgerald reiterated its Overweight rating and kept a $70 price target on Xencor.
- Xencor Announces Initial Plamotamab Data and XmAb657 Study UpdateXencor reported initial dose-escalation data from its Phase 1b study of subcutaneous plamotamab in rheumatoid arthritis and an update on the XmAb657 first-in-human study.
- Xencor Provides Clinical Pipeline and R&D UpdatesXencor announced positive Phase 1b plamotamab data in rheumatoid arthritis and the start of first-in-human testing for XmAb412.
- Positive Phase 3 Results for Elebsiran and Tobevibart Regimen Utilizing Xencor's Xtend TechnologyThe elebsiran and tobevibart regimen, which uses Xencor's Xtend technology, met Phase 3 endpoints and showed sustained viral suppression in chronic hepatitis delta patients.
- Analysts Update Price Targets and Ratings for XencorWells Fargo, RBC Capital Markets and Wedbush updated their ratings and price targets for Xencor on November 2, 2026.
About Xencor, Inc.
Xencor is a clinical-stage biotech company in Pasadena, California that designs engineered antibodies for cancer and autoimmune diseases. What sets it apart is its XmAb protein-engineering platform. Xencor uses it for its own drug candidates, such as T-cell engagers and TL1A antibodies, and also licenses it to larger drugmakers.
How it makes money
Xencor has no approved drugs of its own yet. Its revenue comes from licensing its XmAb technology to partners, which pay royalties, milestones and occasional one-off settlements. Royalties come mainly from Alexion's Ultomiris and Incyte's Monjuvi/Minjuvi, and milestone payments have come from partners such as Astellas and Zenas. In 2026 Alexion agreed to pay about $105 million to settle a dispute over US Ultomiris royalties, which ends those US royalties. Payments on sales outside the US continue. Xencor also holds stakes in partners and sells some of those shares. It mostly runs at a loss, funding research from about $480–500 million of cash it expects to have at the end of 2026.
What usually moves XNCR
- Clinical trial data, such as XmAb819 in kidney cancer and XmAb942 in ulcerative colitis
- Partner royalty and milestone news (Alexion, Incyte, Zenas, Astellas)
- Cash runway and how fast it spends money
- Sentiment toward the biotech sector and changes in interest rates
- FDA decisions on partnered drugs, such as Zenas's obexelimab